SEP 9, 2026 · PHASE 3 TRIAL
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
ClinicalTrials.gov
This is a clinical trial registry record for an active Phase 3 study with no results posted; the record describes planned design and enrollment only.
Reported
Planned enrollment660
Primary outcome measure 1Progression-Free Survival (IRF-assessed), u…
Primary outcome measure 2Overall Survival, up to 26 months